Norrlands Universitetssjukhus starts study with OnZurf Probe
The study aims to further demonstrate the benefits of organ-specific, continuous measurement of metabolic markers. Early detection of lactate withdrawal is an established marker of oxygen deficiency and possible complication. By continuously monitoring changes of different metabolites in the liver with OnZurf Probe, the prerequisites are to gain a greater scientific insight into the liver's function and metabolism after surgery, with the aim of being able to detect and treat complications earlier than is clinically possible today.
OnZurf Probe is a CE-marked sterile disposable product that enables continuous monitoring in gastrointestinal organs such as esophagus, stomach, liver, colon and rectum. The unique Swedish innovation is placed on the surface of an organ without need to penetrate the tissue and thereby cause unnecessary damage or stress to the organ.
"The type of organ-specific measurement that OnZurf Probe enables is unique in its kind, and our hope with the study is to be able to increase understanding of the liver's metabolism by being able to follow the post-operative changes directly on the organ," says Oskar Hemmingsson, Senior Physician at Norrlands Universitetssjukhus (NUS).
NUS is the largest hospital in the northern healthcare region. The hospital is responsible for highly specialized care and service to 876,000 people who live on an area corresponding to over half of Sweden.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on March 25, 2019 08:45.